Home/Journal of Advanced Research (JAR)/Article Record
Peer-Reviewed Article March 4, 2022

iNOS contributes to heart failure with preserved ejection fraction through mitochondrial dysfunction and Akt S-nitrosylation

Are you an author of this work?Link to your sovereign AfriScholar profile
Published in: Journal of Advanced Research (JAR)
Publisher: Elsevier BV • Egypt • 2090-1224
DOI: https://doi.org/10.1016/j.jare.2022.03.003

Abstract

INTRODUCTION: Despite the high morbidity and mortality of heart failure with preserved fraction (HFpEF), there are currently no effective therapies for this condition. Moreover, the pathophysiological basis of HFpEF remains poorly understood. OBJECTIVE: -nitro-L-arginine methyl ester-induced HFpEF mouse model. METHODS: The selective iNOS inhibitor L-NIL was used to examine the effects of short-term iNOS inhibition, whereas the long-term effects of iNOS deficiency were evaluated using iNOS-null mice. Cardiac and mitochondrial function, oxidative stress and Akt S-nitrosylation were then measured. RESULTS: The results demonstrated that both pharmacological inhibition and iNOS knockout mitigated mitochondrial dysfunction, oxidative stress and Akt S-nitrosylation, leading to an ameliorated HFpEF phenotype in mice. In vitro, iNOS directly induced Akt S-nitrosylation at cysteine 224 residues , leading to oxidative stress, while inhibiting insulin-mediated glucose uptake in myocytes. CONCLUSION: Altogether, the present findings suggested an important role for iNOS in the pathophysiological development of HFpEF, indicating that iNOS inhibition may represent a potential therapeutic strategy for HFpEF.

Download Full Text PDFView at PublisherCrossref RecordCrossref XML

Verified Citation Velocity

Recorded scholarly citations in African and international peer-reviewed literature

69
Total Citations

Citations are continuously tracked and harvested across continental OJS endpoints and OpenAlex feeds.